Moderna Settles LNP Patent Dispute
Analysis based on 11 articles · First reported Mar 03, 2026 · Last updated Mar 04, 2026
The settlement is largely positive for Moderna, removing significant legal and financial uncertainties, which led to a jump in its shares. Roivant Sciences===Genevant Sciences and Arbutus Biopharma also saw their shares rise due to the substantial payment, indicating a positive market reaction for all parties involved in the settlement.
Moderna has agreed to pay Roivant Sciences===Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma up to $2.25 billion to settle a long-running legal dispute over the lipid nanoparticle (LNP) technology used in its COVID-19 vaccine. The agreement includes an upfront payment of $950 million in July 2026, with an additional $1.3 billion contingent on a separate legal appeal. This settlement resolves all U.S. and international legal actions accusing Moderna of unauthorized use of LNP technology and eliminates future royalty risks for Moderna's upcoming vaccines. The news led to a more than 10% jump in Moderna's shares, an 11% rise for Arbutus Biopharma, and about 1% for Roivant Sciences. The deal is considered favorable for Moderna, as the total payment represents a small fraction of its past global vaccine sales. This case was set to be the first trial among numerous high-stakes U.S. patent lawsuits concerning COVID vaccine technology, which also involve Pfizer, BioNTech, GSK plc, Bayer, and Alnylam Pharmaceuticals.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard